期刊文献+

FDA批准抗丙型肝炎新药索非布韦(sofosbuvir)上市 被引量:11

FDA approved hepatitis C virus drug Sovaldi(sofosbuvir)
原文传递
导出
摘要 全球丙型肝炎病毒(HCV)的感染率高,且缺少有效的治疗药物。2013年12月6日,美国食品药物监督管理局(FDA)批准新分子实体药物索非布韦(sofosbuvir)片剂上市,商品名Sovaldi,用于慢性丙型肝炎的治疗。索非布韦是一种HCV聚合酶抑制剂,作用于病毒RNA复制的核苷酸类似物NS5B聚合酶位点,能中止病毒复制,是以NS5B聚合酶为靶点的唯一上市品种。本品与聚乙二醇干扰素/利巴韦林或单独与利巴韦林联用,与标准治疗方案相比治愈率更高且缩短给药时间,有广阔的应用前景。 In worldwide, the infection of hepatitis C virus(HCV) is high, but effective treatments were lacking. In December 6, 2013, US Food and Drug Administration(FDA) approved a new drug molecular entity for the tablet of sofosbuvir, with the brand name of Sovaldi. It could treat chronic hepatitis C. As an HCV polymerase inhibitor, sofosbuvir binds to the NS5B active site, causing the termination of RNA chain replication in HCV. For targeting of NS5B polymerase, it is the only approved drug in the world. Sofosbuvir combined with pegylated interferon(Peg-IFN)-ribavirin(RBV) or with only RBV has better effects than standard treatment regimen on improving response rates and reducing treatment time, with broad application prospects.
出处 《药物评价研究》 CAS 2014年第3期285-288,共4页 Drug Evaluation Research
关键词 丙型肝炎 索非布韦 新分子实体 NS5B聚合酶抑制剂 上市新药 hepatitis C sofosbuvir new molecular entity NS5B polymerase inhibitor approved new drug
  • 相关文献

参考文献1

  • 1Michael P Manns,Markus Cornberg.Sofosbuvir: the final nail in the coffin for hepatitis C?[J].The Lancet Infectious Diseases.2013(5)

同被引文献67

  • 1Yuan-Ding Chen,Ming-Ying Liu,Wen-Lin Yu,Jia-Qi Li,Mei Peng,Qing Dai,Xiao Liu Zhen-Quan Zhou From the Central Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, China Kunming Hospital for Infectious Diseases, Kunming 650041, China.Hepatitis C virus infections and genotypes in China[J].Hepatobiliary & Pancreatic Diseases International,2002,1(2):194-201. 被引量:18
  • 2丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 3李金明.感染性疾病血清学检验中应重视对弱反应性标本的确认[J].中华检验医学杂志,2006,29(7):577-580. 被引量:126
  • 4Miriam J Alter.Epidemiology of hepatitis C virus infection[J].World Journal of Gastroenterology,2007,13(17):2436-2441. 被引量:72
  • 5MANNS M P, CORNBERG M. Sofosbuvir: the final nail in the coffin for hepatitis C [ J ]. Lancet Infect Dis, 2013,13(5) : 378 -379.
  • 6HEE B, CHAE S, MEE P, et al. Direct-acting anti- virals for the treatment of chronic hepatitis C: open issues and future perspectives [ J ]. Sci World, 2013, 2013 (5) :704912 - 704920.
  • 7TORRES M R. Sofosbuvir ( GS-7977 ), a pan-geno- type,direct-acting antiviral for hepatitis C virus in- fection[ J]. Expert Rev Anti Infect Ther, 2013,11 (12) :1269 - 1279.
  • 8WANG P Y, CHUN B K, RACHAKONDA S, et al. An efficient and diastereoselective synthesis of PSI- 6130 :a clinically efficacious inhibitor of HCV NS5B polymerase[ J]. J Org Chem,2009,74(17) :6819 - 6824.
  • 9WANG P Y, STEC W, CHUN B K, et al. Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives: EP, 2348029A1 [ P]. 2011 - 07 - 27.
  • 10ROSS B S, SOFIA M J, PAMULAPATI G R, et al. Nucleoside phosphoramidates: WO, 2011123645A3 [ P]. 2011 -10 -06.

引证文献11

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部